Bioverativ (BIVV) News Today → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free BIVV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBiogen Inc 0R1B Stock Quotemorningstar.com - May 25 at 10:21 AMEDU Crosses Above Average Analyst Targetnasdaq.com - April 1 at 10:12 AMBioverativ Makes Splash in Trading Debut, Gaining 18% on Day Onethestreet.com - December 17 at 2:39 PMAmarin Stock: Potential Risks And Rewards (NASDAQ:AMRN) - Seeking Alphaseekingalpha.com - August 14 at 7:25 AMManagement to host conference call today at 4:30 p.m. ET - Form 8-K - Marketscreener.commarketscreener.com - August 5 at 4:45 AMCuris Reports Second Quarter 2022 Financial Results and Business Update - Yahoo Financefinance.yahoo.com - August 4 at 11:45 PMPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Yahoo Financefinance.yahoo.com - July 28 at 5:46 PMPrime Medicine Expands Leadership Team with Key Appointments to Support Continued Growth and Advancement of Prime Editing Technology and Portfolio - Business Wirebusinesswire.com - July 28 at 12:46 PMChancery Holding Amplifies Approach To Boardroom Issues - Law360law360.com - July 21 at 6:48 PMNeuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors - Yahoo Financefinance.yahoo.com - June 14 at 9:11 AMNo Toss For Del. Suit Targeting $11.6B Sanofi-Bioverativ Deal - Law360law360.com - May 27 at 1:43 AMPress Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1 - GlobeNewswireglobenewswire.com - April 28 at 6:05 PMGlobal Next Generation Complement Therapeutics Market Report 2022-2035: Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, RoA - ResearchAndMarkets.com - Business Wirebusinesswire.com - April 4 at 12:56 PMNuvalent Appoints Anna Protopapas as Chair of Board of Directors - PR Newswireprnewswire.com - April 1 at 10:14 PMNuvalent Appoints Anna Protopapas as Chair of Board of Directors - Yahoo Financefinance.yahoo.com - March 31 at 9:59 AMCold Agglutinin Disease Market to Exhibit Massive Growth at a CAGR of 28% in the 7MM for the Study Period of 2019-32 | DelveInsight - Yahoo Financefinance.yahoo.com - March 30 at 6:58 PMWorldwide Gene Editing Beyond CRISPR Industry to 2035 - Featuring Amgen Ventures, ArrowMark Partners and Baxter Ventures Among Others - ResearchAndMarkets.com - Business Wirebusinesswire.com - March 21 at 8:54 AMHormone Refractory Prostate Cancer Market Size [2022-2028] - GlobeNewswireglobenewswire.com - March 19 at 5:58 PMHormone Refractory Prostate Cancer Market Size [2022-2028] to Reach USD 18.35 Billion and Exhibit a CAGR of 9.64% | The Brainy Insights - Yahoo Financefinance.yahoo.com - March 17 at 5:48 AMSigilon Therapeutics (SGTX) Appoints Sarah Yuan as Chief Technical Operations Officer - StreetInsider.comstreetinsider.com - February 22 at 4:42 PMCrinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A. - Yahoo Financefinance.yahoo.com - January 5 at 8:25 AMRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - PRNewswireprnewswire.com - November 30 at 3:28 PMRemedium Bio appoints Dr. Alexey Seregin as Vice President of Research and Development - StreetInsider.comstreetinsider.com - November 29 at 8:19 AMThe Billionaire Chairman Of Vaccine Maker Moderna Wants To Reinvent Scientific Entrepreneurship - Forbesforbes.com - November 15 at 7:51 AMmRNA Synthesis and Manufacturing Services Market Report 2021-2030 - GlobeNewswireglobenewswire.com - October 12 at 8:22 AMmRNA Synthesis and Manufacturing Services Markets, 2021-2030: Success of the Anti-COVID-19 Vaccines has Created an Enormous Need for Consistent Supply of These New Vaccines - PRNewswireprnewswire.com - October 12 at 8:22 AMGlobal Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness - ResearchAndMarkets.com - Business Wirebusinesswire.com - October 5 at 11:23 AMFulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer - StreetInsider.comstreetinsider.com - September 8 at 12:34 PMBioTheryX Announces Appointments of Three New Members to its Board of Directors - PRNewswireprnewswire.com - August 8 at 1:03 PMBioTheryX Announces Appointments of Three New Members to its Board of Directors - Markets Insidermarkets.businessinsider.com - August 8 at 8:03 AMBiogen: Q2 Earnings Insights - Benzingabenzinga.com - July 22 at 9:11 AM Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. BIVV Media Mentions By Week BIVV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIVV News Sentiment▼0.000.42▲Average News Sentiment BIVV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIVV Articles This Week▼00▲BIVV Articles Average Week Get Bioverativ News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIVV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioverativ Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
